QLS1103 / Qilu Pharma - LARVOL DELTA

Safety and tolerability of a novel PARP7 inhibitor QLS1103 in patients with advanced solid tumors: Results from a phase I trial (ESMO Asia 2025) - P1 | "QLS1103 was tolerable and showed potential anti-tumor activity in patients with advanced solid tumors. RP2D of QLS1103 are to be further determined in combined therapeutic strategies."

Clinical • Metastases • P1 data • Breast Cancer • Hormone Receptor Breast Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • TIPARP

QLS1103, A highly potent and selective PARP7 inhibitor treating advanced solid tumors (AACR 2025) - "QLS1103 has exhibited a favorable safety profile with excellent safety margins in preclinical studies and is currently under investigation in a phase I clinical trial. In conclusion, QLS1103 emerges as a promising candidate for the treatment of advanced solid tumors, either as a monotherapy or in combination with immune checkpoint inhibitors, warranting further investigation in clinical settings to fully realize its therapeutic potential."

Metastases • Lung Cancer • Oncology • Solid Tumor • TIPARP

Phase I Study of QLS1103 in Subjects With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=148 | Recruiting | Sponsor: Qilu Pharmaceutical Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Metastases • Oncology • Solid Tumor

Phase I Study of QLS1103 in Subjects With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=148 | Not yet recruiting | Sponsor: Qilu Pharmaceutical Co., Ltd.

Metastases • New P1 trial • Oncology • Solid Tumor